ClinicalTrials.gg
CompletedNCT06150573Updated Jul 24, 2025Results posted

A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching

An interventional study of Test Dentifrice and Reference Dentifrice (Aquafresh Cavity Protection) in Dentin Sensitivity and Oral Hygiene, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 4 under way, none of them phase 3. Dentin Sensitivity · HALEON.

Enrollment
12th of 20
160 · median 185
Started
2023
with 2 others
No phase
18 of 21
2 open now
Registered
6th of 21
by date

Among the 21 studies in Dentin Sensitivity by HALEON, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 with no phase, and was the 6th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Dentin Sensitivity by HALEON, or all of them as a file.
02

Study summary

The main aim of this study is to investigate the ability of an experimental dentifrice containing 5 percent (%) potassium nitrate (KNO3), 1% alumina and 5% sodium tripolyphosphate (STP), to maintain tooth color and reduce extrinsic dental stain accumulation following peroxide tooth bleaching compared to a regular fluoride dentifrice.

Read the detailed description

This will be a randomized, single-blind, single-center, controlled, two arm, stratified (clinically diagnosed dentine hypersensitivity [DH] [Yes/No]), parallel group study to evaluate the efficacy of an experimental dentifrice containing 5% KNO3, 1% alumina and 5% STP, to maintain tooth color and reduce the accumulation of extrinsic tooth stain following peroxide tooth bleaching compared to a regular fluoride-containing dentifrice. The study will recruit generally healthy participants who wish to undergo peroxide tooth bleaching. Sufficient participants will be screened to randomize approximately 160 participants to study treatment to ensure approximately 128 evaluable participants complete the study.

03

Conditions studied

  • Dentin Sensitivity
  • Oral Hygiene

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is of either sex and any gender who, at the time of screening, is between the ages of 18-65 years, inclusive.
  • Participant is willing and able to comply with scheduled visits, and other study procedures and restrictions.
  • Participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history (for example, a medical condition confirmed to be causing xerostomia), or upon oral examination, that would impact the participant's safety, wellbeing or the outcomes of the study, if they were to participate in the study, or affect the participant's ability to understand and follow study procedures and requirements.
  • Participant who is willing and able to undergo at-home tooth bleaching with peroxide containing treatment unsupervised.
  • Participant with generally good oral health that fulfil all of the following:

    1. Teeth suitable for peroxide bleaching and gradable for tooth color and suitable for MLSI evaluation with no significant defects, calculus, restorations, crowns or veneers that could impact peroxide tooth bleaching performance or study evaluations as judged by the clinical examiner.
    2. Facial surfaces of maxillary anterior 6 teeth (tooth numbers 6-11) [Universal tooth number system] with mean Vita Bleached guide shade greater than or equal to (>=)13 at Visits 1 and 2.
    3. Having no lesions of the teeth or oral cavity that could interfere with the study evaluations.
    4. Having a minimum of 16 natural teeth.

Exclusion criteria

Exclusion Criteria:

  • Participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • Participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 60 days prior to study entry and/or during study participation.
  • Participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • Participant who is pregnant (self-reported) or intending to become pregnant over the duration of the study or who is breastfeeding.
  • Participant with known or suspected intolerance or to the study materials [including the peroxide bleaching treatment] (or closely related compounds) or any of their stated ingredients.
  • Participant who, in the opinion of the investigator or medically qualified designee, has a condition that would impact on their safety or wellbeing or affect their ability to understand and follow study procedures and requirements or who should not participate in the study for other reasons.
  • Participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  • Participant with a recent history (within the last year) of alcohol or other substance abuse.
  • Participant with gross periodontal disease or who has had treatment for periodontal disease (including surgery) within 12 months of Screening or who has had scaling or root planning within 3 months of Screening.
  • Participant who has had a peroxide tooth bleaching procedure (either professionally dispensed or at-home [including peroxide-containing dentifrices]) within 12 months of Screening.
  • Participant who has had a dental prophylaxis within 8 weeks of screening.
  • Participant who has used tooth desensitizing treatment (for example dentifrice, mouthwash et cetera) within 2 weeks of screening.
  • Participant with a fixed or removable partial prosthesis, multiple dental implants or orthodontic braces/bands or fixed retainer or togue/lip piercing which, in the opinion of the investigator, could impact study outcomes.
  • During the study period, participant taking daily doses of medication/treatments which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of tooth sensitivity (examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquillizers, antidepressants, mood-altering and anti-inflammatory drugs). Participant will be allowed to use analgesics ad hoc to manage pain.
  • Participant who has tooth abnormalities such as cracking or gross caries lesions that may, in the opinion of the investigator, impact the ability to evaluate tooth sensitivity.
  • Participant who has previously been enrolled in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Test Dentifrice

    Participants will dose the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.

    Drug: Test Dentifrice

  • Active comparator
    Reference Dentifrice

    Participants will dose the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.

    Drug: Reference Dentifrice (Aquafresh Cavity Protection)

Interventions

  • DrugTest Dentifrice

    Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.

  • DrugReference Dentifrice (Aquafresh Cavity Protection)

    Dentifrice containing 1150 ppm fluoride as sodium fluoride.

06

What researchers measure

Primary outcomes

  1. Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching

    Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

    Time frame: At Week 24 after tooth bleaching

Secondary outcomes

  1. Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching

    Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

    Time frame: At Week 12 after tooth bleaching

  2. Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching

    Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

    Time frame: At Week 12 and Week 24 after tooth bleaching

  3. Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites

    Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

    Time frame: At Week 12 and Week 24 after tooth bleaching

  4. Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching

    Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.

    Time frame: At Week 12 and Week 24 after tooth bleaching

  5. Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching

    Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.

    Time frame: At Week 12 and Week 24 after tooth bleaching

07

Results

Posted Jul 24, 2025

Participant flow

This study was conducted at a single center in the United States.

Participant flow — Overall Study
MilestoneTest DentifriceReference Dentifrice
Started7981
Completed7579
Not completed42
Withdrew: Did not meet study criteria10
Withdrew: Adverse event10
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryAdjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching

Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

Time frame:
At Week 24 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching
score on a scaleTest DentifriceReference Dentifrice
Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching12.00 ± 0.35512.06 ± 0.348
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.9141 · Adjusted mean difference: -0.05 · 95% CI -1.04 to 0.93
SecondaryAdjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching

Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.

Time frame:
At Week 12 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching
score on a scaleTest DentifriceReference Dentifrice
Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching12.08 ± 0.35311.71 ± 0.346
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.4583 · Adjusted mean difference: 0.37 · 95% CI -0.61 to 1.34
SecondaryAdjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

Time frame:
At Week 12 and Week 24 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
score on a scaleTest DentifriceReference Dentifrice
Week 120.69 ± 0.0440.87 ± 0.043
Week 240.72 ± 0.0531.03 ± 0.052
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.0042 · Adjusted mean difference: -0.18 · 95% CI -0.30 to -0.06
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = <0.0001 · Adjusted mean difference: -0.31 · 95% CI -0.46 to -0.17
SecondaryAdjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.

Time frame:
At Week 12 and Week 24 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
score on a scaleTest DentifriceReference Dentifrice
Mean Gingival MLSI, Week 120.02 ± 0.0120.03 ± 0.011
Mean Gingival MLSI, Week 240.01 ± 0.0140.05 ± 0.014
Mean Interproximal MLSI, Week 121.37 ± 0.0881.71 ± 0.086
Mean Interproximal MLSI, Week 241.44 ± 0.1052.04 ± 0.103
Mean Body MLSI, Week 120.00 ± 0.0070.01 ± 0.007
Mean Body MLSI, Week 240.00 ± 0.0050.01 ± 0.004
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.2478 · Adjusted mean difference: -0.02 · 95% CI -0.05 to 0.01
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.0957 · Adjusted mean difference: -0.03 · 95% CI -0.07 to 0.01
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.0063 · Adjusted mean difference: -0.34 · 95% CI -0.58 to -0.10
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = <0.0001 · Adjusted mean difference: -0.60 · 95% CI -0.89 to -0.31
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.1536 · Adjusted mean difference: -0.01 · 95% CI -0.03 to 0.01
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.1166 · Adjusted mean difference: -0.01 · 95% CI -0.02 to 0.00
SecondaryAdjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.

Time frame:
At Week 12 and Week 24 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
score on a scaleTest DentifriceReference Dentifrice
Week 120.55 ± 0.0250.69 ± 0.024
Week 240.57 ± 0.0270.74 ± 0.027
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = <0.0001 · Adjusted mean difference: -0.14 · 95% CI -0.21 to -0.07
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = <0.0001 · Adjusted mean difference: -0.18 · 95% CI -0.25 to -0.10
SecondaryAdjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching

Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.

Time frame:
At Week 12 and Week 24 after tooth bleaching
Reported as:
Least squares mean · score on a scale
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
score on a scaleTest DentifriceReference Dentifrice
Week 120.46 ± 0.0230.52 ± 0.023
Week 240.48 ± 0.0270.60 ± 0.026
Statistical analysis
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.0400 · Adjusted mean difference: -0.07 · 95% CI -0.13 to -0.00
  • Test Dentifrice vs Reference Dentifrice · ANOVA · p = 0.0010 · Adjusted mean difference: -0.12 · 95% CI -0.20 to -0.05

Adverse events

Collected over From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Dentifrice0/79 (0%)1/79 (1.3%)39/79 (49.4%)
Reference Dentifrice0/81 (0%)1/81 (1.2%)42/81 (51.9%)
Most frequent serious events
Most frequent serious events
EventTest DentifriceReference Dentifrice
TRANSIENT ISCHAEMIC ATTACKNervous system disorders1/790/81
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/791/81
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTest DentifriceReference Dentifrice
GINGIVAL PAINGastrointestinal disorders15/7921/81
TRAUMATIC ULCERInjury, poisoning and procedural complications15/7919/81
HYPERAESTHESIA TEETHGastrointestinal disorders9/7915/81
ORAL MUCOSAL EXFOLIATIONGastrointestinal disorders7/792/81
ANGULAR CHEILITISGastrointestinal disorders4/790/81
CHRONIC CHEEK BITINGGastrointestinal disorders3/791/81
GINGIVAL DISCOMFORTGastrointestinal disorders3/790/81
NAUSEAGastrointestinal disorders1/790/81
ORAL DISCOMFORTGastrointestinal disorders1/790/81
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/790/81

Baseline characteristics

The Safety population comprised all randomized participants who received at least one dose of the study product.

Age, Continuous
Age, Continuous(years)Test DentifriceReference DentifriceTotal
Mean42.0 ± 11.9137.6 ± 13.0439.8 ± 12.65
Sex: Female, Male
Sex: Female, Male(Participants)Test DentifriceReference DentifriceTotal
Female474592
Male323668
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test DentifriceReference DentifriceTotal
Hispanic or Latino222143
Not Hispanic or Latino5760117
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Test DentifriceReference DentifriceTotal
African American/African Heritage131326
Asian - East Asian Heritage112
Asian - Japanese Heritage101
Asian - South East Asian Heritage7512
Native Hawaiian or Other Pacific Islander4610
White - Arabic/North African Heritage437
White - White/Caucasian/European Heritage424183
Multiple71219
08

Study locations

1 site
  • Silverstone Research Group
    Las Vegas, Nevada 89146, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2024, 7 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 7 months is above that.

Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Nov 29, 2023
StartActual
Nov 27, 2023
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Results first posted
Jul 24, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06150573
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Nov 27, 2023
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Results posted
Jul 24, 2025
Last update
Jul 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion